Efficacy and safety of semaglutide in non-alcoholic fatty liver disease

查看全文 作　　者：Kai [1]Zhu;Rohan [1]Kakkar;Daljeet [2,3]Chahal;Eric M [2,3]Yoshida;Trana [3,4]Hussaini

机构地区：[1]Internal Medicine,University of British Columbia,Vancouver V5Z 1M9,BC,Canada;[2]Department of Gastroenterology,University of British Columbia,Vancouver V5Z 1M9,BC,Canada;[3]BC Liver Transplant Program,Vancouver General Hospital,Vancouver V5Z 1M9,BC,Canada;[4]Pharmaceutical Sciences,University of British Columbia,Vancouver V5Z 1M9,BC,Canada

出　　处：《World Journal of Gastroenterology》索引2023年第29卷第37期,共12页

摘　　要：BACKGROUND Non-alcoholic fatty liver disease(NAFLD)is the leading cause of chronic liver disease.The prevalence and disease burden of NAFLD are projected to exponentially increase resulting in significant healthcare expenditures and lower healthrelated quality of life.To date,there are no approved pharmacotherapies for NAFLD or non-alcoholic steatohepatitis(NASH).Semaglutide has glycemic and weight loss benefits that may be advantageous for patients with NAFLD.AIM To investigate the efficacy and safety of semaglutide in patients with NAFLD.METHODS MEDLINE,CENTRAL,and EMBASE were searched from inception to May 1,2023,to identify eligible randomized controlled trials(RCTs).Meta-analysis was performed using random effects model expressing continuous outcomes as mean differences(MD)or standardized MDs(SMD),and dichotomous outcomes as odds ratios(OR)with 95%confidence intervals(CI).Statistical heterogeneity was assessed using the Cochran’s Q test and I2 statistic.RESULTS Three RCTs involving 458 patients were included.Semaglutide increased the likelihood of NASH resolution(OR:3.18,95%CI:1.70,5.95;P<0.001),improvement in steatosis(OR:2.83,95%CI:1.19,6.71;P=0.03),lobular inflammation(OR:1.81,95%CI:1.11,2.96;P=0.02),and hepatocellular ballooning(OR:2.92,95%CI:1.83,4.65;P<0.001),but not fibrosis stage(OR:0.71,95%CI:0.15,3.41;P=0.67).Radiologically,semaglutide reduced liver stiffness(SMD:-0.48,95%CI:-0.86,-0.11;P=0.01)and steatosis(MD:-4.96%,95%CI:-9.92,0.01;P=0.05).It also reduced alanine aminotransferase(MD:-14.06 U/L,95%CI:-22.06,-6.07;P<0.001)and aspartate aminotransferase(MD:-11.44 U/L,95%CI:-17.23,-5.65;P<0.001).Semaglutide led to improved cardiometabolic outcomes,including decreased HgA1c(MD:-0.77%,95%CI:-1.18,-0.37;P<0.001)and weight loss(MD:-6.53 kg,95%CI:-11.21,-1.85;P=0.006),but increased the occurrence of GIrelated side effects(OR:3.72,95%CI:1.68,8.23;P=0.001).Overall risk of serious adverse events was similar compared to placebo(OR:1.40,95%CI:0.75,2.62;P<0.29).CONCLUSION Semaglutide is effective in the treatment of NAFLD while maintaining a well-tolerated safety profile.Future studies are required to evaluate its effects on fibrosis regression and different phases of NAFLD. 关键词：Non-alcoholic fatty liver disease Fatty liver Metabolic-associated fatty liver Semaglutide

相关文献

参考文献（35）
引证文献（9）
耦合文献（0）

参考文献(35)

引证文献(9)

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

Efficacy and safety of semaglutide in non-alcoholic fatty liver disease

参考文献(35)

引证文献(9)

用户提示